$104 Million is the total value of Pettee Investors, Inc.'s 85 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TRV | New | Travelers | $212,000 | – | 2,000 | +100.0% | 0.20% | – |
| CLVLY | New | Clinuvel Pharmaceuticals | $127,000 | – | 37,000 | +100.0% | 0.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-04
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Johnson & Johnson | 40 | Q3 2023 | 17.3% |
| JPMorgan Chase | 40 | Q3 2023 | 8.0% |
| Exxon Mobil | 40 | Q3 2023 | 9.3% |
| Pfizer | 40 | Q3 2023 | 6.0% |
| Procter & Gamble | 40 | Q3 2023 | 4.8% |
| Bristol-Myers Squibb | 40 | Q3 2023 | 4.1% |
| Nestle ADR | 40 | Q3 2023 | 3.4% |
| PepsiCo | 40 | Q3 2023 | 3.4% |
| Intel | 40 | Q3 2023 | 3.3% |
| Disney | 40 | Q3 2023 | 3.1% |
View Pettee Investors, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-09 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-10-20 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-05 |
| 13F-HR | 2023-01-25 |
| 13F-HR | 2022-11-09 |
| 13F-HR | 2022-07-25 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-11 |
View Pettee Investors, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.